

Index

- Ablated volume, dimensions of, 246
- Ablation catheter
 - nine-array, 81–82
 - seven-array, use with hypertonic saline infusion in tissues, 83
- Ablation phase, of tumor treatment, 276–280
- Ablation zones, size of, for treating liver metastases, 32–35
- Abscess
 - differentiating from osteoid osteoma, 162
 - identifying with computed tomography imaging, 254
- Acoustic noise, in magnetic resonance imaging, exposure limits, 282
- Agar tissue phantom model, for studying saline volume and concentration, 16
- Alcohol abuse, and choice of treatment for hepatocellular carcinoma, 97–98
- Algorithms
 - pulsing, Radionics application, 13
 - for radiofrequency ablation
 - of breast cancer, phase II prospective study, 156
 - of liver tumors, 73, 93
 - for treating hepatic masses, 189
- American College of Radiology Imaging Network, multiinstitutional trial of therapy for pain in osseous metastasis, 177
- American College of Surgeons Oncology Group, clinical trials by, of intraarterial therapy for cancer metastatic to the liver, 63
 - clinical trials by, of operative radiofrequency ablation with hepatic arterial infusion, 42–43
- American Society of Clinical Oncology, 177
- Anesthesia, for radiofrequency ablation of osteoid osteomas, 164
- Animal studies, of radiofrequency ablation
 - in the kidney, 187–188
 - in the lung, 198–200
- Approaches
 - access to the hepatic arterial system, 51
 - for radiofrequency ablation, 71–72
 - complications specific to, 129–131
 - of liver tumors, 98–99
- Assessment
 - minimizing risk preoperatively, in radiofrequency ablation of the liver, 122–125
 - pathologic, of tumor kill after radiofrequency ablation, 154
 - of quality of life, after radiofrequency ablation of liver tumors, 83
 - See also* Evaluation
- Balloon occlusion, for limiting vascular inflow during treatment of liver metastases, 34–35
- Baseline, for imaging to detect recurrent disease, 265–266
- Bile ducts, sensitivity to elevated temperature, 73
- Bioheat equation, 5–6
- Biopsy
 - fine-needle aspiration, at the time of intraoperative ultrasound examination, 232, 238
 - of lesions identified with laparoscopic ultrasonography, 79
 - in osteoid osteoma management, 166
- Bipolar arrays, of electrodes, 9

- Blood flow
 effects of, on tumor-heat interaction, 17–18
 hepatic
 effect on thermal ablation of metastases, 42
 to metastatic cancers, 51
- Blood loss, after cryoablation of hepatocellular carcinomas, 100
- Bone, tumors of, osteoid osteoma, 159–172
- Bonopt Penetration Set, for osteoid osteoma approach, 165
- Breast cancer/carcinomas
 early-stage, radiofrequency ablation of, 137–158
 magnetic resonant imaging of, to follow
 complete ablation of hepatic metastases, 256–257
- Breast conservation therapy, issues in follow-up, imaging modalities, 155
- Calcifications, identifying breast cancer with, as a limitation in radiofrequency ablation, 152–153
- Carcinoembryonic antigen (CEA), level of, predictive of successful hepatic resection, 69
- Carcinoid crisis, preventing prior to radiofrequency ablation for liver metastases, 113
- Carcinoid syndrome, characterization of, 108
- Carcinoid tumors, metastases to the liver, 107–114
 from the small bowel, 244–246
 targeting with magnetic resonance imaging, 276
- Carcinomas
 breast
 early-stage, radiofrequency ablation of, 137–158
 magnetic resonant imaging of, 256–257
 ductal carcinoma in situ, excluding patients from radiofrequency ablation trials, 152
 leiomyosarcoma, metastases to the liver, 115
 images during ablation, 279
 rectal
 incomplete ablation and local recurrence of a hepatic metastasis, 260–261
 radiofrequency ablation of liver metastases of, 31–46
See also Adenocarcinoma; Colon cancer/carcinoma; Colorectal cancer/carcinoma; Hepatocellular cancer/carcinoma; Renal cell carcinoma
- Cardiac arrhythmias, radiofrequency ablation for treating, 31
- Cells, injury to, with increasing temperature, 5
- Chemotherapy
 adjuvant to radiofrequency ablation, 19–21
 for treating liver metastases, 42–43
 intraarterial, combined with radiofrequency ablation for metastatic cancer in the liver, 47–66
 palliative, for metastatic soft tissue sarcomas, 115–116
- Childs's class B cirrhosis, secondary to hepatitis C infection, 95
- Cholecystectomy, in treating liver metastases
 with intraarterial therapy, 58
 with radiofrequency ablation, 39, 78
- Chondroblastoma, differentiating from osteoid osteoma, 162
- Chromogranin, serum levels of, for following carcinoid tumors, 108
- Cirrhosis accompanying hepatocellular carcinoma and choice of treatment, 97–98
 and complications after ablation, 100
- Classification, of recurrence at the site of radiofrequency ablation, 261–262
- Clinical studies/trials
 analysis of, radiofrequency ablation for treating liver metastases, 43–44
 flaws in design of intraarterial chemotherapy, metastases to the liver, 52–54
 pilot, combined radiofrequency ablation and doxorubicin in, 20–21
 randomized
 of the effect of regional chemotherapy after radiofrequency ablation for liver, 42–43
 of hepatic arterial infusion, 52–53
 survival in intraarterial therapy for metastases to the liver, 60
See also Anderson (M.D.) Cancer Center; John Wayne Cancer Institute; Memorial Sloan-Kettering Cancer Center; New York–Weill Cornell Medical Center; Studies
- Cluster arrays, cooled electrode, spacing of electrodes and area of coagulation necrosis, 10–11. *See also* Multielectrode arrays
- Coagulation necrosis
 conditions for, 90
 environment for bacterial growth and abscess formation in, 127–129
 induction of, 4–5
 for treating liver metastases, 32
 in lung tissue, goal of radiofrequency ablation in, 205
 in renal masses, human studies, 190
 volume affected by, limiting factors, 13
- Colon cancer/carcinoma
 local recurrence of hepatic metastasis from, 259, 261–262
 metastases to the liver, computed tomography scans, 40, 254–255
 radiofrequency ablation of liver metastases of, 31–46, 235–238, 247–250, 256–257
 follow-up, 258–259

- Colorectal cancer/carcinoma, metastatic
 response to intraarterial FUDR versus 5-fluorouracil, 52–53
 to the liver, 77
 mechanical occlusion to increase tissue heating, 18
 to the lung, Memorial Sloan-Kettering Cancer Center study, 196
- Combination therapy, with radiofrequency ablation, 19–21
- Complications
 in cryoablation, 138
 hepatic, 101–102, 198
 after hepatic radiofrequency ablation, 121–134
 of percutaneous ethanol injection for hepatocellular carcinoma, 102–103
 pneumothorax, in radiofrequency ablation of lung malignancies, 199
 after radiofrequency ablation, 121–134
 of hepatocellular carcinomas, 100
 in the kidney, animal studies, 187
 of liver tumors, 86
 of lung tumors, 199, 207–208
 of osteoid osteoma, 170
 radiofrequency ablation-specific, 125–129
 after resection of liver, 69
- Computed tomography (CT)
 ablated tumor identification using, 86
 in biopsy and treatment of osteoid osteoma, 165–166
 contrast-enhanced, for evaluating liver metastases after radiofrequency ablation, 39–41
 for evaluating lung lesions after radiofrequency ablation, 208–209
 for follow-up in radiofrequency ablation, 253–267
 for guiding percutaneous placement of electrodes, 190–191
 in lung tumors, 202
 hepatic carcinoid metastasis scan, 109
 hepatocellular cancer scan, in the presence of cirrhosis from hepatitis C infection, 95
 thin-section, to diagnose osteoid osteoma, 161–162
- Conductive pathways, intracardiac, thermal ablation of, 6
- Conductivity, thermal, altering with saline injections, 14–17
- Confirmation phase, of electrode placement, with turbo spin echo (TSE) scans, 276
- Contraindications
 to liver resection, 69
 in hepatocellular carcinoma, 89
 to radiofrequency ablation
 determining with diagnostic laparoscopy, 78–79
 in the liver, in risk of bile duct injury, 249
 in the lung, 200–202
 proximity of lesions to the bile ducts as, 127
- Contrast agents
 for computed tomography confirmation of complete ablation, 254
 for computed tomography or magnetic resonance imaging, for follow-up in recurrence, 264–266
 pattern produced in recurrent liver tumors, 262–264
 for ultrasound confirmation of complete ablation of large lesions, 248
- Cosmetic results, of radiofrequency ablation in breast cancer, questions about, 155
- Criteria
 for radiofrequency ablation of liver tumors, 77
 for resection of pulmonary metastases, 195
- Cryoablation/cryotherapy
 complication rate in, 138
 of liver cancers, unresectable primary, 101–102
 of renal tumors, 186–187
 for treating hepatic malignancies, 198
- Current density, control of, 4
- Cytoreductive surgery, for carcinoid metastases to the liver, 111
- De Gramont regimen, for treating cancer metastatic to the liver, 49
- Dexamethasone, in a clinical trial of intraarterial adjuvant therapy for metastases to the liver, 55
- Differential diagnosis, of osteoid osteoma, 162
- Direct lesional treatment, for metastatic cancer in the liver, 47–50
- Documentation, of radiofrequency ablation using ultrasound, recording devices, 232
- Dosage, of hepatotoxic drugs, in clinical trials of cancer metastatic to the liver, 54–55
- Doxorubicin
 liposome preparation of, effect on necrosis, 20–21
 for treating metastatic soft tissue sarcoma, 115–116
- Drilling, in hard bone, technique, 165–166
- Droperidol, premedication with, in thyroid cancer radiofrequency ablation, 214
- Ductal carcinoma in situ (DCIS), excluding patients with extensive involvement from radiofrequency ablation trials, 152
- Duration
 of ablation at target temperatures, 81, 278
 of heat treatment of malignant cells, 90
- Efficacy, of image guidance, with magnetic resonance imaging, 272

- Electrical conductivity, altering with saline injections, 14–17
- Electrodes
- cool-tip
 - repeated energy application to heat the adjacent area, 278
 - in thyroid cancer ablation, 215
 - internally cooled, 9–10
 - for treating liver metastases, 34
 - length of
 - and duration of radiofrequency application, 10–11
 - and variability of coagulation uniformity, 32–33
 - and variability of electrode temperature, 6
 - umbrella, 7–8
 - See also* Multielectrode arrays
- Embolization
- of the hepatic artery, to treat carcinoid metastases, 112–113
 - of the portal vein, in high volume ratio of tumor to normal liver, 131
 - See also* Occlusion
- Endoscopic retrograde cholangiopancreatography (ERCP), for stenting the biliary system before radiofrequency ablation, 131
- Energy deposition, radiofrequency, 6
- control of, 270–271
- Eosinophilic granuloma, differentiating from osteoid osteoma, 162
- Equipment
- hardware for magnetic resonance imaging systems, 273–275
 - for radiofrequency ablation, 228–230
 - of lung tumors, 202–205
 - for ultrasound guidance, in liver tumor radiofrequency ablation, 230–232
- Evaluation
- for complete ablation, for hepatocellular carcinoma, 264–265
 - of hepatic reserve, 122–125
 - preoperative, of candidates for lung radiofrequency ablation, 200–202
 - of treatment of lung malignancies, positron emission tomography for, 207–209
 - See also* Follow-up; Outcomes
- Exclusion criteria, for studies of radiofrequency ablation for breast cancer, 156
- Extrahepatic disease, and prognosis in hepatic resection, 69
- Failed back syndrome, radiofrequency ablation to treat pain associated with, 175
- Failures in radiofrequency ablation
- of breast cancer, questions about, 154–155
 - of liver tumors, predictors of, 84
- Fatty tissue, thermal conduction by, 153
- Feasibility studies, of radiofrequency ablation for breast cancer, 140–153
- Fentanyl, sedation with, in thyroid cancer radiofrequency ablation, 214
- Ferromagnetic material, restrictions on use of, in magnetic resonance imaging areas, 282
- α -Fetoprotein, tumor marker, level after treatment of hepatocellular carcinoma, 100
- Field strength, apparent needle width variation with changes in, 283
- Financial considerations, in interventional magnetic resonance imaging, 288
- Fine-needle aspiration (FNA), at the time of intraoperative ultrasound examination, 232, 238
- Floxuridine (FURD), metabolism of, in the liver, 51
- 5-Fluorouracil, for treating cancer metastatic to the liver, 49
- Follow-up after radiofrequency ablation
- of liver lesions, 249–250
 - of liver metastases, 41
 - to evaluate quality of life, 83
 - of lung metastases, 208–209
 - of osteoid osteoma, 169
 - of renal tumors, 190
 - See also* Outcomes
- Frameless navigation devices, for magnetic resonance imaging, 274–275
- Frequency encoding direction, 283–284
- Future directions, of image-guided radiofrequency ablation, 288–290
- Gadopentetate dimeglumine, repeat images after ablation using, 278
- Gastrointestinal Stroma Tumor (GIST), hepatic metastasis of, ultrasound-guided radiofrequency ablation of, 115
- Geometry, lesion shape versus tumor shape, 7
- Grounding
- pads for
 - burns at the site of, 126
 - monitoring the temperature at, 82–83
 - as a safety concern, 22–23
 - of the system, safety issues in, 286–287
- Guidance phase, of percutaneous placement of a radiofrequency electrode using magnetic resonance imaging, 275–276
- “Guide-confirm-ablate/monitor” sequence, 278
- Halothane, in radiofrequency ablation, effects on blood flow, 19
- Hardware, for magnetic resonance imaging systems, 273–275

- Hasson technique, for trocar placement, complications of, 129
- Heart, radiofrequency ablation for treating aberrant conduction pathways in, 121
- Heat conduction, in cancellous and cortical bone, 177–180. *See also* Saline infusion
- Heating
 energy needed for, and saline infusion, 16
 therapeutic uses of, 138
 of tissues
 complications related to, 126–127
 by radiofrequency energy, 3
- Heat sink, blood flow as, 17–19
 in the liver, 42, 71–72
 protecting blood vessels in radiofrequency ablation, 96
- Hemoptysis, massive, after radiofrequency ablation of lung tumors, 207–208
- Hemorrhage, after cryoablation of hepatocellular carcinomas, 100–101
- Hepatic dome metastasis, turbo spin-echo images of, 277
- Hepatic malignancies, cryotherapy for ablation of, 198
- Hepatic reserve, and risk in radiofrequency ablation, 122–125
- Hepatitis virus infection
 Childs's class B cirrhosis classification secondary to, 95
 and choice of treatment for hepatocellular carcinoma, 97–98
 clinical, development in intraarterial chemotherapy in the liver, 59
- Hepatocellular cancer/carcinoma
 with cirrhosis from hepatitis C infection, computed tomography scan, 95
 evaluation for complete ablation, before and after contrast agent administration, 264–265
 prognosis in, 69
 radiofrequency ablation of, 89–106
See also Liver tumors
- Herniation pits, differentiating from osteoid osteoma, 162
- Hilar plate, avoiding treating tumors in with radiofrequency ablation, 96
- History, of intraarterial chemotherapy for colorectal cancers metastatic to liver, 50
- Hormones, production of, by carcinoid tumors, 108
- Hounsfield units (HU), to measure density of tissues on a computed tomography image, 86
- Hydropneumothorax, as a complication of percutaneous radiofrequency ablation, 130
- 5-Hydroxyindolacetic acid, for following carcinoid tumors, 108
- Image guidance
 advantages of, for patients not candidates for surgery, 217–222
 in radiofrequency ablation, 152
 of osteoid osteoma, 165–166
 rationale for, 271
 for renal cell carcinoma identification, 185–186
- Images/imaging
 to identify osteoid osteomas, 160–162
 quality of, in magnetic resonance imaging, 273–274
 after radiofrequency ablation, 39–41
 findings, 253–264
 radiofrequency ablation failures related to, 152
 review of, to confirm ultrasound identification of lesions, 232–238
 viewing during interventions, hardware for, 274
See also Interventional magnetic resonance imaging; Magnetic resonance imaging; Positron emission tomography
- Implanted cardiac devices (ICDs), caution in radiofrequency ablation in the presence of, 127–129
- Indications
 for hepatic resection, 68–69
 for radiofrequency ablation
 hepatic, 70, 77
 of hepatocellular carcinoma, 96–98
 in the lung, 200–202
- Infection, as a complication of radiofrequency ablation, 127–129
- Informed consent, for radiofrequency ablation, 83
- Infusion pump, development of, for continuous treatment of metastatic cancer in the liver, 51–52
- Infusion regimen, determining, intraarterial chemotherapy for metastases to the liver, 50–51
- Interferon- α , for treating carcinoid metastases to the liver, 112
- International Registry of Lung Metastases, lung metastasectomy outcomes from, 195
- Interstitial radiofrequency thermotherapy, monitoring the zone of tissue destruction during the procedure, 272–273
- Interventional magnetic resonance imaging, 273–275
 defined, 272
 safety measures for using, 281–282
- Intraarterial chemotherapy combined with radiofrequency ablation, 47–66
- Intraarterial pump, placement in open surgery for radiofrequency ablation of liver metastases, 58–59
- Intraoperative ultrasonography, study of the liver using, prior to radiofrequency ablation, 238

- Irinotecan, for treating cancer metastatic to the liver, 49
- John Wayne Cancer Institute
 feasibility study, of radiofrequency ablation of breast cancers, 142–152
 report of complications in radiofrequency ablation, 121
- Laboratory studies, before and after radiofrequency ablation, 83
- Laparoscopy
 for radiofrequency ablation
 complications in, 129–130
 of hepatocellular carcinoma, 98
 of liver tumors, 77–88
 radiofrequency ablation during, for treating liver metastases, 36–39, 232–249
- Laparotomy
 for radical and partial nephrectomy, 186
 radiofrequency ablation during
 for treating liver metastases, 36–39, 41–42
 for treating liver tumors, 232–249
- Laser-induced thermotherapy, for treating liver tumors, 103
- Leiomyosarcomas, metastases to the liver, 115
 images during ablation, 279
- Leucovorin
 in a clinical trial of intraarterial adjuvant therapy for metastases to the liver, 55
 for treating cancer metastatic to the liver, 49
- Limitations, of radiofrequency ablation for breast cancer, 152–153
- Liposome preparation, doxorubicin, effect on radiofrequency ablation, 20–21
- Liver function
 and choice of treatment, evaluating the volume of remaining functional tissue, 96–98
 tests for, before and after radiofrequency ablation, 100
- Liver tumors
 radiofrequency ablation for treating, 218
 radiographic imaging following radiofrequency ablation of, 253–267
See also Hepat-entries
- Local control, of well-differentiated thyroid cancer, 220–222
- Local recurrence, imaging for following, 259–264
- Location
 of liver metastases
 and approach for radiofrequency ablation, 71–72
 restrictions on radiofrequency ablation due to, 36
 of osteoid osteomas, and suitability for radiofrequency ablation, 162–163
- Lung cancer, treating, 193–194. *See also* Non-small cell lung cancer; Pulmonary malignancies
- Lung Cancer Study Group, prospective randomized trial of limited resection of primary lung cancer, 197
- Lymph node basin, mediastinal, radiation of, in non-small cell lung cancer patients, 197–198
- Lymph node metastasis, in thyroid cancer, 213
- McMasters, Kelly M., clinical trial of intraarterial therapy for cancer metastatic to the liver, 63
- Magnetic resonance imaging (MRI)
 for evaluation
 of radiofrequency ablation of liver metastases, 39–41
 of lung lesions after radiofrequency ablation, 209
 of radiofrequency ablation of liver tumors, 254
 of radiofrequency ablation of lung lesions, 199
 for follow-up of radiofrequency ablation for liver tumors, 253–267
 for guiding radiofrequency ablation of cancer, 269–296
- Magnetic susceptibility effects, considerations in accuracy of needle placement, 283
- Mapping, of ablation zones, using ultrasound images, 38–39
- Mastectomy, following feasibility study of radiofrequency ablation, 146–149
- Material, for needle fabrication, 284–286
- Mathematical model, for studying saline volume and concentration, 16–17
- MD Anderson Cancer Center, The University of Texas
 feasibility study, of radiofrequency ablation of breast cancers, 142–152
 Phase III study, of radiofrequency ablation with intraarterial chemotherapy, 60–63
 radiofrequency ablation of liver tumors under ultrasound guidance, 230–232
- Medazolam, sedation with, in thyroid cancer radiofrequency ablation, 214
- Medical condition, and radiofrequency ablation eligibility, 121
- Medical management versus surgical treatment, for osteoid osteoma, 159–160
- Memorial Sloan-Kettering Cancer Center (MSKCC)
 clinical trial of intraarterial adjuvant therapy for metastases to the liver, 55–57
 study of resection for colorectal lung metastasis, 196

- study of sarcoma metastases to the liver, 114–115
- Metastases
 - intrahepatic colorectal, treating with a clustered, cooled electrode device, 11
 - liver
 - from colon and rectal carcinoma, 31–46
 - treating with radiofrequency ablation and intraarterial chemotherapy, 47–66
 - osseous, radiofrequency ablation of, 173–183
 - pulmonary, surgical therapy for management of, 195–196
- Micrometastatic disease, in the liver, impact of intraarterial FUDR on, 57
- Microwave coagulation therapy, for heat ablation of liver tumors, 103
- Monitoring
 - of radiofrequency ablation
 - of cancer, using magnetic resonance imaging, 269–296
 - of osseous metastases, 175
 - of temperature in tissue, in treating liver metastases, 37
- Morbidity
 - from bone metastases, 174
 - from hormone secretion by hepatic carcinoid metastases, 108
 - in open surgery with intraarterial pump insertion, 58–59
 - operative, in hepatic resection, 67
- Mortality
 - in cryoablation of liver cancers, 198
 - comparison with radiofrequency ablation, 101
 - from hormone secretion by hepatic carcinoid metastases, 108
 - operative, in hepatic resection, 67
 - from vascular injury during laparoscopic radiofrequency ablation, 129–130
 - See also* Survival
- Multielectrode arrays, 7–8, 91
 - for treating liver metastases, 33–34, 79–82
 - See also* Ablation catheter
- Necrosis, evaluating the completeness of, after radiofrequency ablation, 154. *See also* Coagulation necrosis
- Needle-dependent factors in magnetic resonance imaging, 284–286
- Needles
 - for magnetic resonance imaging, 275
 - orientation of, relative to the main magnetic field, 285–286
- Nephrectomy, radical, for treating renal cell carcinoma, 185–186
- Neuroendocrine tumors
 - liver metastases from, 77
 - follow-up after ablation, 85
 - radiofrequency ablation for treating, 112
 - duration of, 244
 - pancreatic, local recurrence of hepatic metastasis from, 262–263
 - See also* Carcinoid tumors
- Neurosurgical applications, of thermal ablation, 6
- New York–Weill Cornell Medical Center
 - feasibility study, of radiofrequency ablation of breast cancers, 142–152
- Non-small cell lung cancer (NSCLC)
 - metastatic to the spine, pain relief in, 179
 - postresection survival by stage, 194
 - radiofrequency ablation of, computed tomography scans, 206
 - resection of, 194–195
- Occlusion
 - balloon, for limiting vascular inflow during treatment of liver metastases, 34–35
 - inflow, during radiofrequency ablation, 98–99
 - mechanical
 - effect on coagulation with cooled electrodes, 18
 - during radiofrequency ablation, 71
 - See also* Pringle maneuver
- Octreotide, for blocking hormone release, before radiofrequency ablation of carcinoid metastases, 113–114
- Open surgery
 - comparison with laparoscopy, for radiofrequency ablation, 87–88
 - for radiofrequency ablation
 - complications in, 129
 - of hepatocellular carcinoma, 98–99
- Osteoarthritis, facet joint, treating pain associated with, 175
- Osteoblastoma, differentiating from osteoid osteoma, 162
- Osteoma, osteoid, radiofrequency ablation of, 31, 159–172, 175, 218
- Outcomes
 - of hepatic resection, 69–70
- Outcomes (*Continued*)
 - of osseous metastasis management, 176–182
 - of osteoid osteoma treatment, 170
 - of radiofrequency ablation
 - of breast cancer, feasibility studies, 152
 - of hepatocellular carcinomas, 100
 - of liver tumors, 84–86
 - of thyroid cancer treatment with radiofrequency ablation, 217
 - See also* Follow-up; Recurrence
- Output, radiofrequency, techniques to improve, 6–12

- Pain
 - in biopsy of osteoid osteoma, 164
 - in percutaneous radiofrequency ablation for liver tumors, 232–233
 - relief of, in thyroid cancer metastatic to the ribs, 180
 - as a response to radiation therapy for osseous metastases, 174, 176–177
 - after treatment of osteoid osteoma, 169
- Palliation
 - from chemotherapy for metastatic soft tissue sarcomas, 115–116
 - of metastatic bone lesions, 174–175
- Pancreas, neuroendocrine tumor of, local recurrence of hepatic metastasis, 262–264
- Papillary thyroid cancer, 213
 - Hurthle cell variant, treated with radiofrequency ablation, 218–220
- Pennsylvania, University of, phase II study of radiofrequency ablation with intraarterial chemotherapy, 61–62
- Percutaneous approach
 - with magnetic resonance imaging-guided needle procedures, safety measures for, 282
 - to radiofrequency ablation
 - complications in, 130–131
 - for hepatocellular carcinoma, 98
 - for liver tumors, 232–233
 - for lung malignancies, 202, 206–207
 - for a metastasis from colon cancer, 235–238
 - versus operative ablation, of liver metastases, 41–43
 - physics of, 3–4
- Percutaneous ethanol injection (PEI), for treating hepatocellular carcinoma, 102–103
- Pharmacologic effects, drugs affecting coagulation diameter, 19
- Phase III trials, of intraarterial chemotherapy adjuvant to radiofrequency ablation in the liver, 63–64
- Physiologic function, evaluation of, for planning surgery for pulmonary malignancies, 196–197
- Picture-in-picture box, laparoscopic and ultrasound images, 79–80
- Placement
 - of grounding pads, 287
 - of a radiofrequency ablation device, technique, 239–242
- Pneumonitis, after radiofrequency ablation of lung malignancies, 207–208
- Pneumothorax
 - in percutaneous radiofrequency ablation, 130
 - in radiofrequency ablation of lung malignancies, 199
- Positron emission tomography (PET), to evaluate treatment of lung malignancies, 207–209
- Power density, radiofrequency, and size of the heat-ablated region, 91
- Power settings, in treatment of lung lesions, 204–205
- Principles, of radiofrequency tissue ablation, 3–28, 227–228
- Pringle maneuver
 - change in coagulation volume with, 18, 34–35
 - in radiofrequency ablation of liver tumors, 233
 - to reduce the time for radiofrequency ablation, liver metastases, 39
- Probes
 - design of, 7–12
 - and complications of radiofrequency ablation, 125
 - for magnetic resonance imaging, 275
- Procedure, of radiofrequency tissue ablation, feasibility study for use in breast cancer, 143–149
- Prognosis, determining, in radiofrequency ablation of breast cancer, 153
- Prophylaxis, for avoiding complications in radiofrequency ablation, 131–132
- Prostate cancer, metastatic to the spine, 181
- Protocols
 - for clinical radiofrequency application, 12–19
 - optimal, for comparing intraarterial therapy with systemic therapy, for metastases to the liver, 51
 - for radiofrequency ablation, 242–244
- Pseudoaneurysms, due to injury from heat in radiofrequency ablation, 127–128
- Pulmonary function, evaluation of, for planning surgery, 196–197
- Pulmonary malignancies, radiofrequency ablation of, 193–211
- Pulse sequence-dependent factors, 283–284
- Pulse sequence sampling bandwidth, 283
- Pulsing, of energy application
 - optimal conditions for, 11–12
 - in radiofrequency ablation for liver metastases, 35
- Quality of life
 - assessment of, after radiofrequency ablation of liver tumors, 83
 - improving with pain relief, in osseous metastatic disease, 174
- Radiation therapy
 - for treating bone metastases, 174
 - versus radiofrequency ablation, 177
 - for treating non-small cell lung cancer, 197–198
- Radiation Therapy Oncology Group, study of response to radiation therapy, for pain in osseous metastasis, 174

- Radical neck dissection, in thyroid cancer with lymph node metastasis, 213
- Radiofrequency ablation
- advantages of, for breast cancer treatment, 138–140
 - complete, imaging for follow-up, 253–259
 - incomplete, imaging for follow-up, 259–264
 - operative versus percutaneous, 41–43
 - percutaneous, of human renal tumors, 188–191
 - for treating hepatic malignancies, comparison with resection, 67–76
- Radiofrequency current deposition, safety concerns in, 287
- Radiofrequency energy, safety issues in the use of, 286–287
- Radiofrequency interstitial thermal ablation (RF-ITA), 270–271
- Radiographic imaging, following radiofrequency ablation of liver tumors, 253–267
- Radioisotope scanning, to identify osteoid osteomas, 160–162
- Randomized trials. *See* Clinical studies/trials; Studies
- Rectal carcinoma, hepatic metastases from
- incomplete ablation and local recurrence of, 260–261
 - radiofrequency ablation of, 31–46
- Recurrence
- with distant metastasis, liver computed tomography scans, 265
 - of hepatocellular carcinoma
 - in cryotherapy versus radiofrequency ablation, 102
 - after percutaneous ethanol injection, 103
 - of liver malignancies
 - outside the ablation site, 264
 - after radiofrequency ablation, 249–250
 - of liver metastases, repeated radiofrequency ablation due to, 83
 - of osteoid osteoma, after radiofrequency ablation, 170
 - of thyroid cancer, after radiofrequency ablation, 220–221
 - and tumor size, in treated liver metastases, 44
See also Follow-up
- Regional therapy, for treating metastatic cancer in the liver, 47–49
- Renal cell carcinoma
- metastasis from
 - magnetic resonance imaging of ablation, 281–282
 - treating, 176, 178–180
 - von Hippel–Landau (VHL) disease associated with, 188–189
- Renal tumors, solid, radiofrequency ablation of, 185–192
- Resection
- limited, for treating lung malignancies, 197
 - of liver tumors, radiofrequency ablation as a alternative to, 121
 - radiofrequency ablation in conjunction with, 72–73
 - for treating hepatic malignancies
 - carcinoid metastases, 110–111
 - comparison with radiofrequency ablation, 63–76, 96–98
 - for treating lung malignancies, alternatives to, 197–209
- Reserve, hepatic, evaluating before radiofrequency ablation, 122–125
- Risk in hepatic radiofrequency ablation, assessment of, 121–125
- automatic power adjustment by, 243–244
- Safety
- of magnetic resonance imaging-guided radiofrequency ablation, 280–282
 - of radiofrequency techniques, 21–23, 286–287
 - with magnetic resonance imaging, 272
- Saline infusion
- for improving tissue heat conduction, 14
 - during radiofrequency ablation
 - of liver metastases, 34, 83
 - of liver tumors, 228–230
 - volume and concentration studies, 16–17
- Saltz regimen, for treating cancer metastatic to the liver, 49
- Sarcomas
- metastases of, to the liver, 114–117
 - prediction of failure in ablation of liver tumors, 85
 - pulmonary, metastasectomy of, 5-year survival rate, 195
- Scanning, radioisotope, to identify osteoid osteomas, 160–162
- Sedation, during radiofrequency ablation of osseous metastases, 175
- Sentinel node biopsy, in feasibility study of radiofrequency ablation in breast cancer, 146
- Side effects
- of embolization of the hepatic artery, 113
 - of interferon- α for treating carcinoid tumors, 112
- Size
- of ablation zones, strategies to increase, 32–35
 - creating spheres of ablation for large tumors, 247–248
 - of hepatocellular carcinomas, and number of deployments of the electrodes, 99
 - of lesions, in ultrasound-guided radiofrequency ablation, 244–249
 - of osseous metastases, and electrode placement, 175–176

- Software, for magnetic resonance imaging, 275
- Somatostatin analogues, for treating carcinoid tumors, 111–112
- Southwest Oncology Group, clinical trial of intraarterial adjuvant therapy for metastases to the liver, 55–57
- Spheres of ablation, creating, for large tumors, 247–248
- Spinal axis, malignancies in, 177–180
- Stanford University School of Medicine, feasibility study of radiofrequency ablation for treating breast cancer, 141
- Stress fracture, differentiating from osteoid osteoma, 162
- Studies
 - of complications of hepatic radiofrequency ablation, 123–124
 - feasibility, of radiofrequency ablation for treating breast cancer, 141–152
 - of intraarterial hepatic chemotherapy, after surgical resection of colorectal metastases, 55–57
 - preliminary, of radiofrequency ablation for lung malignancies, 208
 - of radiofrequency ablation, of renal tumors, comparison with resection, 189–190*See also* Clinical studies/trials
- Surgery
 - for non-small cell lung cancer, early-stage, 194–195
 - resection of pulmonary metastases, 195–196*See also* Resection
- Survival
 - after intraarterial therapy for metastases to the liver
 - in a clinical trial, 60
 - compared with initial response, 52
 - after percutaneous ethanol injection of hepatocellular carcinoma, 102–103
 - after resection
 - of colorectal liver metastases, 67–76
 - of hepatocellular carcinoma, 89*See also* Mortality
- Systemic chemotherapy
 - for metastatic cancer in bone, 174
 - for metastatic cancer in the liver, 47–49
 - versus intraarterial chemotherapy, 51
 - after resection, studies of, 57
 - for metastatic carcinoid in the liver, 110
- Target lesion
 - in the liver, ultrasound evaluation of, 238–239
 - visualization of, planning for, 282–283
- Technical implications, of follow-up imaging of liver malignancies, 264–266
- Techniques
 - for biopsy and treatment of osteoid osteoma, 165–169
 - for local ablation, comparison of, 101–103
 - open surgical, for radiofrequency ablation in colorectal disease, 58–59
 - for osseous metastasis management, 175–176
 - of radiofrequency tissue ablation, 3–28
 - laparoscopic, 78–84
 - of lung tumors, 202–205
 - in recurrent thyroid cancer, 214–217
 - ultrasound-guided, 232–249
- Temperature
 - for ablation, monitoring
 - to assess the process, 81–82
 - at the periphery of the ablation zone, 83
 - in spinal metastasis management, 180–181
 - electrode surface, during radiofrequency heating, 6
 - optimal
 - for ablation, 5
 - for ablation, effect of fatty tissue on thermal energy conduction, 153
 - for ablation, in breast cancer, 142
 - for thermocoagulation of osseous metastases, 176
 - for treating tumors, 89–90
- Tests, preoperative, for assessing pulmonary risk before resection, 196–197
- Thermal damage, to nontumor tissues, avoiding, 23
- Thermal equilibrium, effect on, of electrode configuration, 12–13
- Thoracic complications, in radiofrequency ablation, 127
- Thoracotomy
 - mini, for radiofrequency ablation of lung tissue, 206
 - open, for radiofrequency ablation application, 201
- Thyroglobulin levels, for following outcomes of radiofrequency ablation of thyroid cancer, 217
- Thyroid cancer
 - metastatic to the ribs, pain relief in, 180
 - recurrent, radiofrequency ablation of, 213–223
- Time, for complete ablation, of hepatocellular carcinomas, 99
- Tissue, local, thermal distribution in, 14–17
- Toxicity, hepatic, in intraarterial chemotherapy, 52–54
- Transducer
 - design of, for liver imaging, 230–232
 - intraoperative views of positions of, liver metastasis treatment, 242–243
- Transplant, liver, for metastatic carcinoid, 111–112

- Tumor markers, α -fetoprotein, 100
- Tumors
- Gastrointestinal Stroma Tumor, 115
 - physiology of, altering to improve radiofrequency thermal ablation, 14
 - renal, 185–192
 - size of
 - and choice of approach for radiofrequency ablation in the liver, 98–99
 - and placement of electrode arrays, 92–94
 - and use of percutaneous thermal ablation, 6, 71, 96
 - and use of radiofrequency ablation, liver metastases, 36–37
 - See also* Carcinoid tumors; Carcinomas; Liver tumors; Neuroendocrine tumors; Specific types of, e.g. Breast cancer/carcinomas
- Turbo spin-echo (TSE) image, during thermal ablation, 280
- Ultrasound/ultrasonography
- changes observed during radiofrequency ablation, 244
 - color flow Doppler
 - for guiding radiofrequency ablation of liver tumors, 230–232
 - to observe blood flow in ablated zones, 82
 - for confirming device placement, in radiofrequency ablation of liver tumors, 240–242
 - for guiding percutaneous placement of electrodes in renal masses, 190–191
 - for imaging and guiding radiofrequency ablation
 - expertise for using, 153
 - of breast cancer, 141
 - of hepatic carcinoid metastasis, 110
 - of liver metastases, 36–38, 79, 92
 - of liver tumors, 227–252
 - of thyroid cancer, 214–216
 - intraoperative, detection of intrahepatic tumors during, 43, 84
 - surveillance, for detecting thyroid cancer recurrence, 213
- University of California–Davis School of Veterinary Medicine, feasibility study of radiofrequency ablation for treating breast cancer, 141
- University of Pittsburgh Medical Center, treatment of lung tumors with radiofrequency ablation, 205
- Variables
- in grounding pad temperature control, 22–23
 - in thermal ablation, 5–6
 - display instruments for, 83
- Vascular inflow, limiting, for treating liver metastases, 34–35
- Vascularity
- of carcinoid metastases, 108–109
 - of tumors, and duration of radiofrequency ablation, 99–100
- Vasopressin, in radiofrequency ablation, effects on blood flow, 19
- Veins, proximity to, effect on complete ablation of large lesions, 249
- Ventricular fibrillation, as a complication of radiofrequency ablation of the liver, 127
- Video-assisted thoracoscopy (VATS), for application of radiofrequency ablation in lung tumor treatment, 201–202
- Visualization, of the ablation device, 283
- Vital structures
- bile duct sensitivity to elevated temperature, 73
 - inadvertent damage to, from thermal insults, 23
 - See also* Cholecystectomy
- Volume, of coagulation, limiting factors in vivo, 13–14
- von Hippel–Landau (VHL) disease, renal cell carcinomas associated with, 188–189
- Wavelength, of radiofrequency energy, 3
- Web site, American College of Radiology Imaging Network, 177
- Wet electrodes
- for kidney radiofrequency ablation, animal studies, 187